Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.40

Mkt cap

5.7M

Volume

41K

High

1.40

P/E Ratio

-1.14

52-wk high

6.80

Low

1.36

Div yield

N/A

52-wk low

0.92

Clearmind Medicine Inc. (CMND) has regained compliance with Nasdaq's minimum bid price requirement, with its common shares maintaining a bid price of $1.00 or greater for 10 consecutive business days. Nasdaq has closed the prior bid price deficiency matter, and the company's scheduled hearing with the Nasdaq Listing Qualifications Hearings Panel has been canceled. Clearmind's common shares will continue to be listed and traded on Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:27 pm

Johnson Controls International plc (NYSE:JCI) shares dropped over 6% due to weaker-than-expected quarterly results, with sales of $6.91 billion missing the $7.09 billion consensus and adjusted EPS of $1.05 below the $1.09 consensus. Other stocks experienced significant movements, with notable gainers including Aditxt, Inc. (ADTX), C4 Therapeutics, Inc. (CCCC), and Icosavax, Inc. (ICVX), among others. Losers included Achieve Life Sciences, Inc. (ACHV), Harbor Custom Development, Inc. (HCDI), and Oracle Corporation (ORCL), with various reasons such as FDA feedback, bankruptcy filing, and missed sales estimates, respectively.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 6:22 pm

Icosavax, Inc. (NASDAQ:ICVX) shares surged approximately 45% in pre-market trading following AstraZeneca's announcement of plans to acquire Icosavax for up to $1.1 billion. Icosavax also reported positive interim Phase 2 results for its IVX-A12 vaccine candidate. Other stocks experiencing pre-market movements include gainers Bruush Oral Care Inc. (BRSH), Connect Biopharma Holdings Limited (CNTB), and losers Harbor Custom Development, Inc. (HCDI), which filed for Chapter 11 bankruptcy, and Oracle Corporation (ORCL), which reported mixed quarterly results.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 1:00 pm

Clearmind Medicine Inc has filed an F-3 form with the SEC for a mixed shelf offering, allowing the company to issue various types of securities up to a total of $50 million.

Portfolio Pulse from Charles Gross

December 11, 2023 | 10:26 pm

U.S. stocks showed mixed performance with the Dow down 0.18%, NASDAQ up 0.19%, and S&P 500 down 0.07%. AutoZone Inc (NYSE:AZO) reported Q1 earnings that exceeded expectations with EPS of $32.55, beating the consensus of $31.57, but sales slightly missed estimates. Information technology shares rose by 0.4%, while materials shares dipped by 1.3%. Clearmind Medicine Inc. (NASDAQ:CMND), Travere Therapeutics, Inc. (NASDAQ:TVTX), and Mercurity Fintech Holding Inc. (NASDAQ:MFH) saw their shares rise significantly. Conversely, Replimune Group, Inc. (NASDAQ:REPL), iBio, Inc. (NYSE:IBIO), and Designer Brands Inc. (NYSE:DBI) experienced substantial share price declines. Oil and gold prices fell, and European shares closed mostly higher. Asian markets mostly closed lower, and economic data showed a decrease in job openings and a rise in the ISM Services PMI.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 7:27 pm

Daktronics, Inc. (NASDAQ:DAKT) shares fell over 10% due to weaker-than-expected quarterly results, with earnings of 5 cents per share versus the estimated 13 cents and sales of $199.37 million against the expected $213.70 million. Other stocks experienced significant movements in Tuesday's mid-day session, with notable gainers including Meiwu Technology Company Limited (WNW), Volato Group, Inc. (SOAR), and Clearmind Medicine Inc. (CMND), among others. Losers included Replimune Group, Inc. (REPL), iBio, Inc. (IBIO), and Designer Brands Inc. (DBI), which all saw substantial declines in their share prices.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 6:06 pm

U.S. stocks were mixed with the Dow Jones falling 100 points and the NASDAQ rising. Consumer discretionary shares were up, while materials shares dipped. The ISM services PMI increased to 52.7 in November, exceeding estimates. Clearmind Medicine, Allarity Therapeutics, and Mercurity Fintech Holding saw stock price increases due to positive company news. Conversely, Replimune Group, iBio, and Designer Brands experienced significant stock price drops following negative announcements. Oil and gold prices were up, while silver and copper declined. European shares were mostly higher, and Asian markets closed mostly lower. U.S. job openings decreased, and the Economic Optimism Index fell.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 5:11 pm

Clearmind Medicine Inc (NYSE:CMND) stock rose after announcing positive results from pre-clinical trials for cocaine addiction treatment using its psychedelic molecule MEAI. The company, which focuses on developing psychedelic-derived therapeutics, also filed a patent application related to cocaine addiction in collaboration with SciSparc's CannAmide. The CEO highlighted the potential paradigm shift in treating cocaine addiction, a condition currently lacking dedicated treatments.

Portfolio Pulse from Adam Eckert

December 05, 2023 | 3:21 pm

The Department of Defense Health Agency is funding a trial for PTSD treatment using Seelos Therapeutics' intranasal ketamine, SLS-002. Cybin Inc. reported strong efficacy in its Phase 2 trial of psilocybin derivative CYB003 for Major Depressive Disorder. Clearmind Medicine announced results from a pre-clinical trial combining its MEAI treatment with SciSparc's PEA for various disorders. Clearmind also underwent a reverse stock split to comply with Nasdaq's minimum bid price rule. Beckley Retreats is launching a new psilocybin retreat program, and Mindbloom is introducing a ketamine therapy program. Seelos Therapeutics launched a public offering, and other companies reported financial results or updates. The AdvisorShares Psychedelics ETF and several psychedelics stocks' trading performance are also highlighted.

Portfolio Pulse from Lara Goldstein

December 05, 2023 | 3:12 pm

Clearmind Medicine shares resumed trading after a circuit breaker halt. The halt was triggered by a significant move in the stock price, which is a common protective measure in the stock market to prevent excessive volatility.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.